Gisslinger, Heinz
Klade, Christoph
Georgiev, Pencho
Krochmalczyk, Dorota
Gercheva-Kyuchukova, Liana
Egyed, Miklos
Dulicek, Petr
Illes, Arpad
Pylypenko, Halyna
Sivcheva, Lylia
Mayer, Jiří
Yablokova, Vera
Krejcy, Kurt
Empson, Victoria http://orcid.org/0000-0003-3819-2370
Hasselbalch, Hans C. http://orcid.org/0000-0003-3936-8032
Kralovics, Robert http://orcid.org/0000-0002-6997-8539
Kiladjian, Jean-Jacques http://orcid.org/0000-0002-8121-438X
Gisslinger, Heinz
Kiladjian, Jean-Jacques
,
Funding for this research was provided by:
This study was supported by research funding from AOP Health
Article History
Received: 15 May 2023
Revised: 4 August 2023
Accepted: 17 August 2023
First Online: 26 August 2023
Competing interests
: HG reports grants and personal fees from AOP Health and Novartis, and personal fees from PharmaEssentia and BMS-Pharma. JM reports grants from AOP Health. RK reports personal fees from AOP Health, PharmaEssentia, Qiagen and Novartis and stock ownership in MyeloPro Diagnostics and Research. HH reports Data Monitoring Board honoraria from AOP Health and grants from Novartis. JJK reports grants and personal fees from AOP Health, and personal fees from Novartis, BMS/Celgene, AbbVie and PharmaEssentia. CK, KK, and VE report that they are employees of AOP Health. The remaining authors declare no competing financial interests.